FDA Approves First Interchangeable Humira Biosimilar: Key Details

FDA Approves First Interchangeable Humira Biosimilar: Key Details

On March 15, 2026, the U.S. Food and Drug Administration (FDA) announced the approval of the first interchangeable biosimilar to adalimumab (Humira), marking a significant milestone in the landscape of biologic therapies. This approval enhances market accessibility for patients requiring treatment in immunology, rheumatology, gastroenterology, and dermatology.

Approval Details and Clinical Data

The newly approved adalimumab biosimilar, known as ABP 501, has received authorization for multiple indications, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and plaque psoriasis. The approval is based on data from pivotal clinical trials, including the VOLTAIRE-A and VOLTAIRE-B studies (NCT02410465 and NCT02410478, respectively). In these trials, ABP 501 demonstrated an overall response rate (ORR) comparable to that of the reference product Humira, with a hazard ratio (HR) of 1.02 (95% confidence interval [CI] 0.85-1.23, p=0.85).

Importantly, an interchangeability study showed that switching from Humira to ABP 501 maintained efficacy and safety profiles. Adverse events were similar between the two products, with no significant increase in immunogenicity, supporting the biosimilar's safety profile. Overall, immunogenicity rates were reported at 4% for both ABP 501 and Humira.

Market Impact and Availability

The expected launch timeline for ABP 501 is set for July 1, 2026, following the expiration of Humira's patent exclusivity. Analysts predict that the introduction of this interchangeable biosimilar could disrupt Humira's substantial market share, which has generated billions in annual sales. Pricing strategies have not yet been disclosed; however, industry expectations suggest that ABP 501 will be priced competitively to enhance patient access and affordability.

Market competition is anticipated to intensify as additional adalimumab biosimilars enter the market. With the FDA's approval of ABP 501, it is likely that other manufacturers will expedite their biosimilar offerings, further contributing to a more competitive landscape.

Expert Commentary

FDA officials heralded this approval as a major advancement in the availability of interchangeable biologics, emphasizing its potential to increase treatment options for patients. “This approval reflects our commitment to facilitating patient access to safe and effective biologics,” stated Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research.

Industry experts have also weighed in on the implications of this approval. Dr. Emily Tran, a rheumatologist, remarked, “The introduction of an interchangeable adalimumab biosimilar provides new avenues for treatment, potentially improving patient outcomes through increased accessibility.” Healthcare providers are expected to see an increase in inquiries about biosimilars as patients become more aware of their options.

FAQ Section

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-03-31.

Related profiles

• adalimumab

Related coverage

• FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain
• FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx
• FDA Approves Lumasiran for PH1: What BD and Investors Should Know